Timing of ARDS Resolution (TARU): A Pragmatic Clinical Assessment of ARDS Resolution in the ICU

Sarah J. Chalmers1,2,4 · Amos Lal1,2 · Ognjen Gajic1,2 · Rahul Kashyap1,3

Received: 1 March 2021 / Accepted: 13 September 2021 / Published online: 29 September 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract

Purpose Lack of a pragmatic outcome measures for acute respiratory distress syndrome (ARDS) resolution is a barrier to meaningful interventional trials of novel treatments. We evaluated a pragmatic, electronic health record (EHR)-based approach toward the clinical assessment of a novel outcome measure: ICU ARDS resolution.

Methods We conducted a retrospective observational cohort study evaluating adult patients with moderate–severe ARDS admitted to the medical intensive care unit (ICU) at Mayo Clinic in Rochester, MN, from January 2001 through December 2010. We compared the association of ICU ARDS resolution vs non-resolution with mortality. ICU ARDS resolution was defined as improvement in \( P/F > 200 \) for at least 48 h or (if arterial blood gas unavailable) \( \frac{S}{F} > 235 \), or discharge prior to 48 h from first \( P/F > 200 \) without subsequent decline in \( P/F \), as documented in EHR.

Results Of the 254 patients included, ICU ARDS resolution was achieved in 179 (70%). Hospital mortality was lower in patients who met ICU ARDS resolution criteria as compared to those who did not (23% vs. 41%, \( p < 0.01 \)). After adjusting for age, gender, and illness severity, the patients who met ICU ARDS resolution criteria had lower odds of hospital mortality [odds ratio 0.47, 95% CI 0.25–0.86; \( p = 0.015 \)].

Conclusion The electronic health record-based pragmatic measure of ICU ARDS resolution is associated with patient outcomes and may serve as an intermediate outcome assessing novel mechanistic treatments.

Keywords Respiratory distress syndrome · Critical illness · Critical care · Prognosis · Hypoxia · Oxygen

Introduction

First described by Ashbaugh et al. [1], acute respiratory distress syndrome (ARDS) remains a common intensive care unit (ICU) diagnosis which is associated with substantial morbidity and mortality and tremendous cost [2]. Despite advances in ARDS treatment and supportive measures, the syndrome and its complications still impose a world-wide burden of disease, and its poor prognosis remains similar over more than a decade [3–6]. ARDS commonly occurs in association with critical illness and has been associated with pulmonary (pneumonia, aspiration, lung contusion, toxic inhalation) and extra-pulmonary risk factors (sepsis, shock, trauma, multiple transfusions, pancreatitis, high-risk surgery) [7].

To date, studies have identified multiple sequelae in ARDS survivors, including a reduction in the quality-of-life, declining functional status, and neurocognitive impairment [8–12]. A few studies have evaluated long-term survival of ARDS patients, though the majority of these studies lack a control group of patients at-risk for comparison [8, 13–16]. One study [17] evaluated long-term survival of ARDS patients compared to a control group; however, this study was published before significant changes in the quality of critical care delivery that has occurred over the past two decades [18–22]. This body of literature highlights the need
for interventional studies that can prevent or effectively treat ARDS.

To date, most interventional trials in patients with ARDS have targeted mortality as the primary outcome [23–29]. Mortality is a late outcome that requires a large study sample size and significant follow-up duration. In addition, mortality in ARDS, similar to COVID or other critical illnesses [30], is often multifactorial and may be due to non-respiratory failure causes and is not the best outcome to measure the effect of trial interventions on the ARDS disease process. Other outcomes have included ventilator-free days (VFD), organ failure-free days, P/F course, and more recently, the ordinal scale utilized by the World Health Organization in clinical trials related to influenza and COVID-19 [23–25, 31–34]. The ordinal scale is highly subjective as the decision to transition from one mode of oxygenation (i.e., ECMO) to another is not standardized and practices vary not only across institutions but also providers. Similarly, VFD may be affected by confounding factors. For instance, in a patient who receives a prolonged course of steroids for treatment of ARDS, while the underlying ARDS process may resolve, the patient may remain on the ventilator for an extended period due to steroid-related myopathy and weakness.

To date, few truly pragmatic outcome measures have been evaluated in this disease. While PF is often used clinically to follow disease course, it has not been studied as a measure used to define resolution of ARDS. A pragmatic outcome measure that is easily obtained and assessed at the bedside and extractable from the electronic health record (EHR) is needed to facilitate future interventional studies.

Thus to identify a pragmatic outcome measure that depicts the evolution of the underlying ARDS process, we evaluated the survival of patients with ARDS who met our new proposed definition of ICU ARDS resolution as compared to those without resolution.

**Materials and Methods**

**Study Design**

This was an observational cohort study utilizing a convenience sample of a previously described case–control study population spanning 10 years (January 2001–December 2010). In the previous case–control study, short- and long-term outcomes of ARDS cases were compared to matched controls via previously published study methodology [35, 36]. This cohort was obtained from Mayo Clinic Hospital in Rochester, Minnesota, which is a large academic tertiary referral center in Olmstead County and with readily available resources including extracorporeal membrane oxygenation. During the cohort study period, our ICU followed a standardized ventilation protocol for all patients meeting the following criteria: the ratio of partial pressure of oxygen to inspired oxygen concentration (P/F) < 300, bilateral infiltrates on chest imaging, no evidence of heart failure, and clinical picture compatible with ARDS. This was very similar to the Berlin definition of ARDS before its official release and widespread acceptance. The ventilator management protocol consisted of lung-protective ventilation strategies including low tidal volumes (6 ml/kg ideal body weight), table-based FiO2 and PEEP titration to target SpO2 88–92%, and plateau pressure goal of < 30 cm H2O. Volume-targeted assist control was the recommended ventilator mode; however, a pressure-targeted strategy was allowed with the caveat that tidal volumes should not exceed 6 ml/kg of ideal body weight. Daily sedation holiday and standardized weaning protocols were also in place at that time. Our study was approved by the Mayo Clinic Institutional Review Board (IRB # 08-003560). All patients with prior informed consent on file were considered for participation.

**Study Population**

Eligible patients included all adult residents of Olmsted County, Minnesota, admitted to the ICU with moderate–severe ARDS within 24 h of admission and requiring invasive ventilation. Those patients who did not have ARDS on admission but subsequently developed ARDS were identified using a previously validated electronic surveillance tool [37]: these selected patients were verified by subsequent medical record review. Inclusion criteria were prompted by an electronic alert designed to recognize the following combination of observations: (1) qualifying arterial blood gas analysis: P/F < 200 and (2) qualifying chest radiograph report (free text Boolean query containing trigger words: “bilateral” AND “infiltrate” OR “edema”). Moderate–severe ARDS was defined by the following criteria: P/F < 200 on PEEP ≥ 5 mmHg with bilateral lung infiltrates on chest x-ray and absence of evidence of left atrial hypertension. ICU ARDS resolution was defined as improvement in P/F > 200 for at least 48 h or, if arterial blood gas unavailable, SpO2:FiO2 (S/F) > 235, or discharge prior to 48 h from first P/F > 200 without subsequent decline in P/F.

Patients who were admitted for comfort care only, those who died within 24 h of admission or within 48 h of ARDS onset, and those readmitted to the hospital during the study period were excluded. Per Mayo policy, all patients who receive care at our institution receive information regarding the use of their medical records for research purposes. Patients who had previously declined the use of their medical records for research purposes were excluded from this study (approximately 5% of hospitalized Olmsted County residents).
Outcomes Measures

The primary outcome was hospital mortality. All blood gas results (PaO₂) and inspired oxygen (FiO₂) values were obtained from the database and combined to create P/F ratios for each lab draw interval. If PaO₂ measurements were not available, corresponding S/F ratio was used. Subjects were sorted by medical record numbers and date of onset (earliest to later), such that all results were listed sequentially for each patient. All available P/F during patients’ index ICU admission were used in the analysis.

Statistical Analysis

Data were expressed as mean (standard deviation), median (interquartile range), and proportion as appropriate. Baseline characteristics and severity of illness were compared using Wilcoxon’s signed rank test for continuous variables and McNemar’s chi-square test for categorical variables. The degrees of freedom were set to number of categories − 1 to account for the number of possible outcomes when testing the statistical significance of the difference in outcomes for cases and controls surviving hospitalization. Long-term survival was depicted with Kaplan–Meier survival curves. The p value cutoff of ≤ 0.05 was used for statistical significance. Statistical analyses were performed using SAS (version 9.3, SAS Institute, Cary, NC).

Results

During the defined study period, 282 patients met the inclusion criteria of ARDS onset within 24 h of admission to the ICU. Twenty-eight patients died in the first 48 h following ARDS onset and were excluded from the study. Patient characteristics are listed in Table 1. Of the remaining 254 patients, 179 patients met the criteria for ICU ARDS resolution and 75 patients did not. When evaluating by worst P/F, 129 were classified as moderate ARDS and 125 were classified as severe ARDS. Between the two groups, there was no difference in median age, gender, or admission APACHE III score. There was a significant difference in worst mean P/F during the study period with a lower P/F in those with non-resolution [median (IQR) 81 (60–115) vs 138 (81–187); p < 0.001]. For those with ICU ARDS resolution as compared to those without, the median age was 68 (inter-quartile range [IQR] = 55–79) and 67 (IQR 60–77; p 0.53) years, 99 (55%) and 46 (61%; p 0.41) were male, and admission APACHE III score was 46 (IQR 33–59) vs 50 (IQR 38–68; p 0.08). Unadjusted hospital mortality was lower in patients who met ICU ARDS resolution compared to those who did not (23% vs. 41%, p < 0.01). After adjusting for age, gender, and admission APACHE III, the patients who met ICU ARDS resolution criterion were less likely to die (odds ratio [OR] 0.47, 95% confidence interval = 0.25–0.86, p = 0.015). This difference in survival persisted when these patients were followed for 6 months which is illustrated in the survival curve (Fig. 1). A sensitivity analysis was completed evaluating only those with sustained P/F < 200 (P/F < 200 for at least the first 24 h). The trend of hospital mortality for sustained moderate–severe ARDS was 41% (p = 0.025). In addition, we observed the trend in P/F (Fig. 2). During their ICU stay, while initial mean P/F were similar between the two groups, patients with ICU ARDS resolution demonstrated an increasing trend in mean P/F and an increase

Table 1 Characteristics and outcomes of patients with acute respiratory distress syndrome resolution and those with non-resolution

|                      | ARDS resolution (N=179) | ARDS non-resolution (N=75) | p-value |
|----------------------|-------------------------|---------------------------|---------|
| Age in years         | Median (IQR) 68 (52–80) 67 (60–77) | 0.53               |
| Gender (male) n (%)  | 99 (55) 46 (61)         | 0.41               |
| ICU admission APACHE III | Median (IQR) 46 (33–59) 50 (38–68) | 0.08               |
| Worst P/F            | Median (IQR) 138 (81–188) 81 (60–115) | <0.001* |
| Hospital mortality n (%) | 41 (23) 31 (41)         | <0.01* |
| ARDS severity by worst P/F | Moderate 129 125        | 0.41               |

Fig. 1 Survival curve; blue—patients with intensive care unit acute respiratory distress syndrome resolution. Red—patients without intensive care unit acute respiratory distress syndrome resolution
over time, while those without resolution demonstrated a progressive decline. Events in the first 90 days (death, ARDS resolution, ICU discharge, and last follow-up) occurring from ARDS onset in patients with and without ICU ARDS resolution are seen in Fig. 3.

**Fig. 2** Temporal PaO$_2$/FiO$_2$ trends during ICU stay

**Fig. 3** Events since acute respiratory distress syndrome onset in patients with and without acute respiratory distress syndrome resolution

**Discussion**

In our study, adult patients who were admitted to the ICU with moderate–severe ARDS requiring mechanical ventilation and who met our suggested ICU ARDS resolution criteria had a lower risk of hospital mortality. This suggests that our proposed ICU ARDS resolution definition can be used as an intermediate marker to predict the patient outcome of mortality and can be used for future studies. In addition, while the initial mean $P/F$ was similar between the two groups, patients with ICU ARDS resolution had a temporal increase in $P/F$ as compared to the non-resolution group. This further differentiates these two populations and highlights the predictive nature of the $P/F$, the physiologic variable in our resolution definition that illustrates the change in the underlying disease process. Interestingly, this pre-COVID cohort demonstrated a relatively rapid median time to resolution. This is in line with previously published data demonstrating an increasing prevalence of rapidly resolving ARDS [38].

This study identifies our newly proposed definition of ICU ARDS resolution as an early and pragmatic outcome measure that is easily obtained from standard lab measures obtained in most ICU patients with ARDS. In addition, if PaO$_2$ measures are not available, $S/F$ ratio, which is easily obtained at the bedside or from the EHR, can be substituted. This has important implications for future clinical trials as an early and pragmatic marker occurs earlier in the disease
process allowing for shorter trial duration and hence lower trial cost.

Our study does have limitations. In our definition of ICU ARDS resolution, we chose to define resolution as $P/F > 200$, despite Berlin criteria which defines the presence of ARDS by $P/F < 300$. The cut-off point of $P/F > 200$ was chosen based on conventional weaning guidelines that recommend using a $P/F$ of $>150–200$ as oxygenation criteria as part of the evaluation for consideration of extubation [39]. Our inclusion criteria utilized the Berlin definition which was published after the end date of this cohort collection. Although this population may have been classified differently at the time of their illness (ARDS per American European Consensus Conference definition), the Berlin definition showed minimal improvement in prognostication over the AECC criteria and certainly, it is advisable to use the most current definition on a retrospective cohort. Use of the worst $P/F$ ratio as our daily assessment of resolution has limitations as a single measurement may not reflect the overall picture of the patient on any given day. However, we chose this measurement in an attempt to limit overestimation and for pragmatic use in further clinical and research applications. Our study also did not assess the contribution of the intensity of mechanical ventilation such as would be done if the oxygenation index was used. As noted above, the purpose of this study was to evaluate a pragmatic marker of ARDS resolution and ventilator measurements such as mean airway pressure cannot be reliably extracted from the EHR. In addition, as discussed above, our ventilator protocol at that time did consist of lung protective strategies and best practices for the care of critically ill patients with ARDS (including sedation holidays and spontaneous awakening trials). Therefore, this variation in classification is of little to no significance. Several studies have described subtypes of ARDS such as pulmonary and extra-pulmonary types. We did not differentiate these groups in our study; however, while several characteristics (i.e., lung mechanics) differ between these two groups, mortality does not differ and therefore, differentiating these groups would not affect our study outcome [40–42]. This single-center experience in a discrete population of southern Minnesota residents may not be generalizable to a broader population and would require larger studies for external validation. In addition, the retrospective nature of our study does not allow for consideration of potential physician variation in evaluation and management of the patients and we are limited by the data available which did not allow us to adjust for other confounding variables such as adjunctive therapies. However, as previously mentioned, well-established protocolized ventilator management practices were in place during the study period and evaluation of the impact of treatment methods is beyond the scope of this study whose aim was to evaluate the intermediate outcome measure, ICU ARDS resolution. In addition, other than lung-protective ventilation and prone positioning, adjunctive interventions and therapies have not definitively demonstrated reduction in mortality. Our cohort was completed prior to completion of guidelines recommending use of prone positioning. Further studies will be needed for external validation of this marker.

Conclusion

In our cohort study, the proposed definition of ICU ARDS resolution was associated with the patient outcomes and may serve as an intermediate surrogate outcome in future quality improvement projects, cohort studies, and clinical trials.

Acknowledgements We would like to thank Michael Malinchoc, MS, Division of Biostatistics, Mayo Clinic, Rochester, MN, for his consultation and expertise on the statistical analytics in this study.

Author Contributions SJC, OG, and RK contributed to the study design and data acquisition. SJC, AL, OG, and RK contributed to the analytical data evaluation. SJC and RK were responsible for drafting of the manuscript. All authors contributed significant intellectual input and critical appraisal of the manuscript. All authors have given their approval of this version of the manuscript and agree to accountability on all of manuscript aspects.

Funding No funding was required for this project.

Data Availability All data and materials are stored in a password-protected electronic file at Mayo Clinic and are available for review.

Declarations

Conflict of interest The authors have no financial or non-financial disclosures. The authors do not have conflict/competing interests related to this manuscript.

Ethical Approval Our study was approved by the Mayo Clinic Institutional Review Board (IRB # 08-003560).

Consent to Participate Per Mayo Clinic policy, patients who had previously declined the use of their medical record data were excluded from this study.

References

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet (London, England) 2(7511):319–323. https://doi.org/10.1016/s0140-6736(67)90168-7
2. Yadav H, Thompson BT, Gajic O (2017) Fifty years of research in ARDS. Is acute respiratory distress syndrome a preventable disease? Am J Respir Crit Care Med 195(6):725–36. https://doi.org/10.1164/rccm.201609-1767CI

3. Bellani G, Laffey JG, Pham T et al (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315(8):788–800. https://doi.org/10.1001/jama.2016.0291

4. Ranieri VM, Rubenfeld GD, Thompson BT et al (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307(23):2526–2533. https://doi.org/10.1001/jama.2012.5669

5. Villar J, Blanco J, Añón JM et al (2011) The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 37(12):1932–1941. https://doi.org/10.1007/s00134-011-2380-4

6. Zambon M, Vincent JL (2008) Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 133(5):1120–1127. https://doi.org/10.1378/chest.07-2134

7.Gattinoni L, Pelosi P, Suter PM, Vercesi P, Lissoni A (1998) Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med 158(1):3–11. https://doi.org/10.1164/ajrccm.158.1.9708031

8. Herridge MS, Tansey CM, Matté A et al (2011) Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364(14):1293–1304. https://doi.org/10.1056/NEJMoa1018822

9. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme JF Jr (2005) Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med 171(4):340–347. https://doi.org/10.1164/rccm.200406-763OC

10. Angus DC, Mustafa A, Clermont G et al (2001) Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 163(6):1389–1394. https://doi.org/10.1164/ajrccm.163.6.2005123

11. Davidson TA, Caldwell ES, Curtis JR, Hudson LD, Steinberg KP (1999) Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 281(4):354–360

12. Dowdy DW, Eid MP, Dennison CR et al (2006) Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Med 32(8):1115–1124. https://doi.org/10.1007/s00134-006-0217-3

13. Cheung AM, Tansey CM, Tomlinson G et al (2006) Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 174(5):538–544. https://doi.org/10.1164/rccm.200505-693OC

14. Wang CY, Calfee CS, Paul DW et al (2014) One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. Intensive Care Med 40(3):388–396. https://doi.org/10.1007/s00134-013-3186-3

15. Needham DM, Colantuoni E, Mendez-Tellez PA et al (2012) Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. BMJ 344:e2124. https://doi.org/10.1136/bmj.e2124

16. Yilmaz M, Iscimen R, Keegan MT et al (2007) Six-month survival of patients with acute lung injury: prospective cohort study. Crit Care Med 35(10):2303–2307

17. Davidson TA, Rubenfeld GD, Caldwell ES, Hudson LD, Steinberg KP (1999) The effect of acute respiratory distress syndrome on long-term survival. Am J Respir Crit Care Med 160(6):1838–1842. https://doi.org/10.1164/ajrccm.160.6.9903058

18. The Acute Respiratory Distress Syndrome Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342(18):1301–1308. https://doi.org/10.1056/NEJM200005043421801

19. Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368–1377. https://doi.org/10.1056/NEJMoa010307

20. Annane D, Sebille V, Bellissant E (2006) Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 34(1):22–30

21. Pronovost PJ, Rinke ML, Emery K, Dennison C, Blackledge C, Berenholtz SM (2004) Interventions to reduce mortality among patients treated in intensive care units. J Crit Care 19(3):158–164

22. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41(2):580–637. https://doi.org/10.1097/CCM.0b013e31827e83af

23. McAuley DF, Laffey JG, O’Kane CM et al (2014) Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371(18):1695–1703. https://doi.org/10.1056/NEJMoa1403285

24. Paine R 3rd, Standiford TJ, Dechert RE et al (2012) A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 40(1):90–97. https://doi.org/10.1097/CCM.0b013e31822d7bf0

25. Network TACT, National Heart L, Institute B, Health Nlo (2002) Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 30(1):1–6

26. Herold S, Hoegner K, Vadážs I et al (2014) Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Crit Care Med 189(5):609–611. https://doi.org/10.1164/rccm.201311-2041LE

27. Sud S, Friedrich JO, Taccone P et al (2010) Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med 36(4):585–599. https://doi.org/10.1007/s00134-009-1748-1

28. Guérin C, Reignier J, Richard JC et al (2013) Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 368(23):2159–2168. https://doi.org/10.1056/NEJMoa1301140

29. (2019) Early neuromuscular blockade in the acute respiratory distress syndrome. Lancet Respir Med 8(1):12. https://doi.org/10.1016/s2213-2600(20)30165-x

30. Gainnier M, Roch A, Forel J-M (2004) Effect of neuromuscular blockade on mortality of patients treated in intensive care units. J Crit Care 19(3):158–164

31. Gainnier M, Roch A, Forel J-M (2004) Effect of neuromuscular blockade on mortality of patients treated in intensive care units. J Crit Care 19(3):158–164

32. Ho ATN, Patolia S, Guervilly C (2020) Neuromuscular blockade of acute lung injury and acute respiratory distress syndrome. Crit Care Med 38(10):20131-20132

33. Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383(19):1813–1826. https://doi.org/10.1056/NEJMoa2007764

34. Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799. https://doi.org/10.1056/NEJMoa2001282

35. Ahmed AH, Litell JM, Malinchoc M et al (2013) The role of potentially preventable hospital exposures in the development of acute respiratory distress syndrome: a population-based study. Crit Care Med. https://doi.org/10.1097/CCM.0b013e318298a6dB
36. Thakur SJ, Trillo-Alvarez CA, Malinchoc MM et al (2010) Towards the prevention of acute lung injury: a population based cohort study protocol. BMC Emerg Med 10:8. https://doi.org/10.1186/1471-227X-10-8
37. Herasevich V, Pickering BW, Dong Y, Peters SG, Gajic O (2010) Informatics infrastructure for syndrome surveillance, decision support, reporting, and modeling of critical illness. Mayo Clin Proc 85(3):247–254. https://doi.org/10.4065/mcp.2009.0479
38. Schenck EJ, Oromendia C, Torres LK, Berlin DA, Choi AMK, Siempos II (2019) Rapidly improving ARDS in therapeutic randomized controlled trials. Chest 155(3):474–482. https://doi.org/10.1016/j.chest.2018.09.031
39. MacIntyre NR (2001) Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 120(6):375S–395S. https://doi.org/10.1378/chest.120.6_suppl.375S
40. Agarwal R, Srinivas R, Nath A, Jindal SK (2008) Is the mortality higher in the pulmonary vs the extrapulmonary ARDS? A meta analysis. Chest 133(6):1463–1473. https://doi.org/10.1378/chest.07-2182
41. Hall JB (1998) Respiratory system mechanics in adult respiratory distress syndrome. Am J Respir Crit Care Med 158(1):1–2. https://doi.org/10.1164/ajrccm.158.1.ed06-98
42. Pelosi P, D’Onofrio D, Chiumello D et al (2003) Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J 22(42 suppl):48s–56s. https://doi.org/10.1183/09031936.03.00420803

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.